Clinical trial · Interventional
A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection
Eastern Hepatobiliary Surgical Hospital
NCT00819650CI-TRIAL-00021590completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to analyze the therapeutic effect of adjuvant Licartin therapy after resection.Patients receiving curative resection (R0) were randomized to postoperative Licartin group and no Licartin group. The time to recurrence ,the overall survival as well as the incidence of complications after therapy was observed to confirm the role of adjuvant therapy of Licartin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Licartin (generic name,[131I]metuximab injection) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Licartin
- description
- patients who receive Licartin therapy after liver resection
- interventionNames
- Drug: Licartin (generic name,[131I]metuximab injection)
- type
- NO_INTERVENTION
- label
- placebo
- description
- control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive Licartin therapy after liver resection
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 2010
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with HCC who received curative liver resection (R0)and with positive expression of HAb18G/CD147 in the HCC tissues 2. Karnofsky Performance Score performance over 60 3. The functions of the kidney, heart and lung and the blood system are normal and fittable for Licardin therapy. 4. The liver function is of grade A or B in Child-Pugh classification. 5. Patients give consent to the test. Exclusion Criteria: 1. Negative expression of HAb18G/CD147 in the HCC tissues 2. Allergic history to biologic products(Licartin) 3. Any of the situation list below: WBC less than 2000/ml, Hb less than 90g/L or PLT less than 50000/ml, bilirubin level more than 2.5 times the upper limit of normal value, serum albumin less than 32 g/l. 4. Severed disease of the heart, lung, kidney, brain and blood system. 5. Other severed disease might affect the trial . 6. Patients would not sign the consent to the trial.
References
Publications (1)
- DERIVEDLi J, Xing J, Yang Y, Liu J, Wang W, Xia Y, Yan Z, Wang K, Wu D, Wu L, Wan X, Yang T, Gao C, Si A, Wang H, Wu M, Lau WY, Chen Z, Shen F. Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2020 Jun;5(6):548-560. doi: 10.1016/S2468-1253(19)30422-4. Epub 2020 Mar 9. PMID 32164877